PUBLISHER: IMARC | PRODUCT CODE: 1379146
PUBLISHER: IMARC | PRODUCT CODE: 1379146
The global home infusion therapy market size reached US$ 40.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 59.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.7% during 2022-2028. The rising prevalence of chronic diseases, the increasing preference for home healthcare, and ongoing product innovations represent some of the key factors driving the market.
Home infusion therapy is a specialized medical treatment involving the administration of medication, such as antivirals or immune globin, fluids, or nutrition intravenously through various equipment, including pumps, catheters, and vials, to patients in the comfort of their homes. It is recommended for patients with infections, cancer, or chronic conditions like multiple sclerosis (MS) or rheumatoid arthritis requiring long-term or frequent infusion therapy. Home infusion therapy offers comfort and convenience, improves the quality of life, and reduces the risk of hospital-acquired infections. In addition to this, it allows patients to maintain a sense of independence and control over their treatment while still receiving the necessary medical care. Home infusion therapy is highly effective in chemotherapy and hydration, enteral, inotropic, anti-infective, nutritional, and pain management therapies that are primarily used for treating diabetes and various gastrointestinal and oncological disorders.
The rise in the number of people suffering from chronic diseases, such as cancer, osteoarthritis, human immunodeficiency viruses (HIV), and diabetes, represents one of the prime factors driving the market growth. Concurrent with this, the increase in the geriatric population prone to life-threatening diseases and requiring regular medical attention, such as infusion therapy, is positively impacting the market growth. Moreover, the implementation of numerous government initiatives and favorable reimbursement policies and the surging costs of extended hospital stays are prompting patients to opt for home infusion therapy, which, in turn, is contributing to the market growth. Besides this, the shifting preference for home healthcare services due to their convenience and cost-effectiveness and the growing need for space and beds in hospitals are strengthening the market growth. In line with this, the rising prevalence of hospital-acquired infections (HAIs) due to elongated exposure to contaminated equipment, bed linens, and air droplets is aiding in market expansion. In addition to this, the widespread demand for specialty drugs which require specialized administration is acting as another significant growth-inducing factor. Furthermore, innovative technological advancements, such as the development of lightweight, portable, and easy-to-use infusion pumps equipped with advanced drip systems for precise and real-time monitoring of IV treatments, are presenting remunerative growth opportunities for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global home infusion therapy market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product and application.
The report has provided a detailed breakup and analysis of the home infusion therapy market based on the product. This includes infusion pumps (elastomeric, electromechanical, gravity, and others), intravenous sets, IV cannulas, and needleless connectors. According to the report, infusion pumps represented the largest segment.
A detailed breakup and analysis of the home infusion therapy market based on the application has also been provided in the report. This includes anti-infective, endocrinology (diabetes and others), hydration therapy (athletes and others), chemotherapy, enteral nutrition, parenteral nutrition, specialty pharmaceuticals, and others. According to the report, anti-infectives accounted for the largest market share.
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for home infusion therapy. Some of the factors driving the North America home infusion therapy market included the expanding prevalence of cancer, HIV, and diabetes, the widespread adoption of home healthcare, and numerous technological advancements in the industry.
The report has also provided a comprehensive analysis of the competitive landscape in the global home infusion therapy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Eli Lilly and Company, Fresenius SE & Co. KGaA, ICU Medical Inc., JMS Co. Ltd., Nipro Corporation, Option Care Health Inc. (Walgreen Co.), Smiths Group plc, and Terumo Corporation. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.